Search
Research
Making a Killer: Selecting the Optimal Natural Killer Cells for Improved ImmunotherapiesOver the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching.
Research
Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint TherapyWith immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others identified beneficial immunological effects of the vitamin A derivative tretinoin on anti-tumour immunity.
Research
An immunometabolomic approach to unmask developmental regulation of innate immunity and asthma riskDeborah James Pat Strickland Read Holt PhD PhD, DSc, FRCPath, FRCPI, FAA Head, Pregnancy and Early Life Immunology Honorary Research Associate
News & Events
Research into innovative treatments for asthma and antibiotic-resistant infections fuelled by Stan Perron Charitable Foundation grantsNew funding from the Stan Perron Charitable Foundation will support research into innovative treatments for antibiotic-resistant infections and asthma in children, led by Wal-yan Respiratory Research Centre researchers.
Research
Oestrogen amplifies pre-existing atopy-associated Th2 bias in an experimental asthma modelThe role of oestrogen in experimental atopic asthma, and guide future research on sex-related variations in atopic asthma susceptibility/intensity
Research
The Impact of Unfavourable Climatic Conditions on Children and FamiliesThis project aims to explore the impacts of unfavourable climatic conditions on children and families.
Research
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive CombinationsAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.
Research
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of actionChemotherapy has historically been the mainstay of cancer treatment, but our understanding of what drives a successful therapeutic response remains limited.
Research
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytesImmune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response.
Research
The interplay between sarcoma and surgery-induced wound healingIn this project, we are using systems biology approaches to map the wound healing response in sarcoma following surgery to identify new treatments that can prevent sarcoma relapse.